Novartis AG (NVS) | Statement of Comprehensive Income
See also
- Johnson & Johnson (JNJ), Comprehensive Income
- Pfizer Inc. (PFE), Comprehensive Income
- Merck & Co. Inc. (MRK), Comprehensive Income
- GlaxoSmithKline PLC (GSK), Comprehensive Income
- Abbott Laboratories (ABT), Comprehensive Income
- Sanofi (SNY), Comprehensive Income
- Novo Nordisk A/S (NVO), Comprehensive Income
- UnitedHealth Group Inc. (UNH), Comprehensive Income
- Bristol-Myers Squibb Co. (BMY), Comprehensive Income
- AstraZeneca PLC (AZN), Comprehensive Income
- Eli Lilly & Co. (LLY), Comprehensive Income
- Medtronic Inc. (MDT), Comprehensive Income
- Baxter International Inc. (BAX), Comprehensive Income
ˇ Show More
Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
You have visited 10 password protected pages for free. Others contain data covered by 
.
Sign Up Now to get full access to whole website and cut out all advertisements.
Novartis AG, Consolidated Statement of Comprehensive Income
USD $ in millions
| 12 months ended | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
|---|---|---|---|---|---|---|
 |
Net income from continuing operations | |
|
|
|
|
|
Fair value adjustments on financial instruments, net of taxes | |
|
|
|
|
|
Actuarial gains (losses) from defined benefit plans, net of taxes | |
|
|
|
|
|
Novartis share of equity recognized by associated companies, net of taxes | |
|
|
|
|
|
Revaluation of previously owned non-controlling interest | |
|
|
|
|
|
Currency translation effects | |
|
|
|
|
|
Net income from discontinued operations | |
|
|
|
|
|
Other comprehensive income | |
|
|
|
|
|
Comprehensive income | |
|
|
|
|
|
Comprehensive income attributable to non-controlling interests | |
|
|
|
|
|
Comprehensive income attributable to shareholders of Novartis AG | |
|
|
|
|
| Item | Description | The company |
|---|---|---|
| Fair value adjustments on financial instruments, net of taxes | Gross appreciation or the gross loss in value of the total unsold securities at the end of an accounting period, after tax, attributable to the parent entity. | Novartis AG's fair value adjustments on financial instruments, net of taxes declined from 2009 to 2010 but then slightly increased from 2010 to 2011. |
| Actuarial gains (losses) from defined benefit plans, net of taxes | Net changes to accumulated comprehensive income during the period related to benefit plans, after tax, attributable to the parent entity. | Novartis AG's actuarial gains (losses) from defined benefit plans, net of taxes declined from 2009 to 2010 and from 2010 to 2011. |
| Currency translation effects | Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax, attributable to the parent entity. | Novartis AG's currency translation effects declined from 2009 to 2010 and from 2010 to 2011. |
| Comprehensive income attributable to shareholders of Novartis AG | The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent. | Novartis AG's comprehensive income attributable to shareholders of Novartis AG declined from 2009 to 2010 and from 2010 to 2011. |
Stock Analysis on Net (www.stock-analysis-on.net)
Copyright © 2012 EBIT Financial Analyses Center